Niacin therapy unhelpful, occasionally harmful, study says

March 9, 2013

A combination drug containing niacin failed to lower the risk of heart attacks or strokes and even proved harmful for some with vascular disease, a study released Saturday reported.

Niacin, also known as , has for years been widely prescribed to lower "bad" LDL cholesterol and raise levels of "good" .

The link between high levels of and heart disease is well-documented, and doctors work to mitigate that risk with diet and as well as a variety of medications.

But even with these protocols in place, heart disease and stroke claim lives and cause damage, so scientists continue searching for ways to improve the treatment.

Niacin—in doses about 100 times higher than the recommended amount from food—was thought to be helpful.

Indeed, the used in the study—made by US Merck and combining extended release niacin with laropiprant—is already approved in 70 countries, though not the US.

But when tested against a placebo in more than 25,000 patients, it failed to reduce the numbers of heart attacks, strokes or other serious .

Even more worryingly, the study showed unexpectedly higher levels of bleeding and infections in the group taking the drug versus the placebo.

And the group taking the study drug also showed higher levels of other side effects, including new cases of diabetes and complications for previously-diagnosed diabetes, as well as rashes and diarrhea.

"We are disappointed that these results did not show benefits for our patients", said Jane Armitage, lead author of the study, which included more than 25,000 subjects.

But she and her fellow authors said the result is important, because it gives evidence that the risks of niacin outweigh the benefits when used with current treatments.

Armitage said it was unlikely the poor outcome could be linked to the second component of the drug, laropiprant, which was included to reduce the facial flushing caused by niacin.

The lack of benefit on heart attacks and strokes is consistent with another recent, smaller-scale study of niacin, which did not use laropiprant, and many of the side effects are known to be due to niacin, she explained.

Because of the results of this research, Merck has withdrawn its application for FDA approval of the drug and suspended its sale around the world.

Explore further: Merck says cholesterol drug failed to show benefit

Related Stories

Merck says cholesterol drug failed to show benefit

December 20, 2012
Drugmaker Merck & Co. said it will not seek U.S. approval for its cholesterol drug Tredaptive and is recommending doctors abroad stop prescribing it to new patients, based on failed study results.

HPS2-THRIVE trial: Side-effects cause a quarter of heart patients to stop treatment

February 26, 2013
The largest randomised study of the vitamin niacin in patients with occlusive arterial disease (narrowing of the arteries) has shown a significant increase in adverse side-effects when it is combined with statin treatment.

Raising 'good' cholesterol levels reduces heart attack and stroke risk in diabetes patients

October 7, 2011
Increasing levels of high-density lipoproteins, better known as HDL or "good" cholesterol, reduced the risk for heart attack and stroke among patients with diabetes. That's according to a new study appearing online today ...

Niacin does not reduce heart attack, stroke risk in stable CV patients

November 15, 2011
In patients whose bad cholesterol is very well-controlled by statins for a long time period, the addition of high-dose, extended release niacin did not reduce the risk of cardiovascular events, including heart attack and ...

NIH stops clinical trial on combination cholesterol treatment

May 26, 2011
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned. The trial found that adding high dose, ...

Recommended for you

Five vascular diseases linked to one common genetic variant

July 27, 2017
Genome-wide association studies have implicated a common genetic variant in chromosome 6p24 in coronary artery disease, as well as four other vascular diseases: migraine headache, cervical artery dissection, fibromuscular ...

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.